Renovaro Biosciences Inc (RENB) - Total Assets
Based on the latest financial reports, Renovaro Biosciences Inc (RENB) holds total assets worth $8.23 Million USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Renovaro Biosciences Inc - Total Assets Trend (2012–2025)
This chart illustrates how Renovaro Biosciences Inc's total assets have evolved over time, based on quarterly financial data. Also see RENB company net worth for the company's overall valuation and market capitalisation.
Renovaro Biosciences Inc - Asset Composition Analysis
Current Asset Composition (June 2025)
Renovaro Biosciences Inc's total assets of $8.23 Million consist of 1.2% current assets and 98.8% non-current assets. Review RENB total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.1% |
| Accounts Receivable | $1.11 Million | 0.7% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $30.04K | 0.0% |
| Goodwill | $159.33 Million | 97.7% |
Asset Composition Trend (2012–2025)
This chart illustrates how Renovaro Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See current stock price of Renovaro Biosciences Inc for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Renovaro Biosciences Inc's current assets represent 1.2% of total assets in 2025, a decrease from 100.0% in 2012.
- Cash Position: Cash and equivalents constituted 0.1% of total assets in 2025, down from 2.5% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 97.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is goodwill at 97.7% of total assets.
Renovaro Biosciences Inc Competitors by Total Assets
Key competitors of Renovaro Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Renovaro Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.04 | 0.06 | 7.29 |
| Quick Ratio | 0.04 | 0.06 | 7.29 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-28.11 Million | $-19.65 Million | $5.23 Million |
Renovaro Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between Renovaro Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.33 |
| Latest Market Cap to Assets Ratio | 0.16 |
| Asset Growth Rate (YoY) | 0.0% |
| Total Assets | $163.13 Million |
| Market Capitalization | $26.19 Million USD |
Valuation Analysis
Below Book Valuation: The market values Renovaro Biosciences Inc's assets below their book value (0.16x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Renovaro Biosciences Inc's assets decreased by 0.0% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Renovaro Biosciences Inc (2012–2025)
The table below shows the annual total assets of Renovaro Biosciences Inc from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $163.13 Million | 0.00% |
| 2024-06-30 | $163.13 Million | +179.81% |
| 2023-06-30 | $58.30 Million | -31.11% |
| 2022-06-30 | $84.63 Million | -55.36% |
| 2021-06-30 | $189.61 Million | +6.46% |
| 2020-06-30 | $178.10 Million | -0.99% |
| 2019-06-30 | $179.88 Million | -1.44% |
| 2018-06-30 | $182.50 Million | +3935.74% |
| 2017-06-30 | $4.52 Million | +419.29% |
| 2016-06-30 | $870.83K | -83.38% |
| 2015-06-30 | $5.24 Million | +947.98% |
| 2014-06-30 | $500.00K | +2404.63% |
| 2013-06-30 | $19.96K | +47.27% |
| 2012-06-30 | $13.55K | -- |
About Renovaro Biosciences Inc
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands. It operates through two segments, RENB and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors… Read more